Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.14015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pityriasis Lichenoides Chronica-Like Mycosis Fungoides: A Diagnostic Dilemma.
Skinmed
January 2025
Department of Skin & VD, Civil Hospital, BJ Medical College, Ahmedabad, Gujarat, India.
Mycosis fungoides (MF) is a neoplasm of the immune system. It is a cutaneous lymphoma originating in the peripheral epidermotropic T-cells, specifically the memory T-cells (CD45RO+). The etiology of MF is indefinite, but various factors, such as genetic and epigenetic abnormalities, environmental and occupational exposure to chemicals, infections, and cytokines (interleukin [IL]-2, IL-4, etc.
View Article and Find Full Text PDFThe Risk of Developing Keratinocyte Malignancies in Patients with Cutaneous T-cell Lymphoma.
J Invest Dermatol
December 2024
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA. Electronic address:
Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides.
An Bras Dermatol
December 2024
Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Seyrantepe, İstanbul, Turkey.
Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).
Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.
Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study.
Case report: Canadian consensus on chlormethine gel use in mycosis fungoides-CTCL: literature review and real-world experience.
Front Med (Lausanne)
December 2024
Division of Radiation Oncology, University of Montreal, Montreal, QC, Canada.
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment.
View Article and Find Full Text PDFPractical recommendations for therapy and monitoring of mogamulizumab patients in Germany.
J Dtsch Dermatol Ges
December 2024
Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!